Citigroup Inc Tiziana Life Sciences LTD Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$0.65 - $1.29 $65 - $129	-100 Reduced 2.7%	3,605 $2,000
Q1 2023 May 11, 2023	SELL	$0.51 - $1.1 $1,785 - $3,850	-3,500 Reduced 48.58%	3,705 $4,000
Q4 2022 Feb 09, 2023	SELL	$0.56 - $0.78 $12,101 - $16,855	-21,610 Reduced 75.0%	7,205 $4,000
Q3 2022 Nov 10, 2022	BUY	$0.55 - $0.83 $14,155 - $21,362	25,738 Added 836.46%	28,815 $22,000
Q2 2022 Aug 10, 2022	SELL	$0.66 - $1.06 $162,969 - $261,738	-246,923 Reduced 98.77%	3,077 $2,000
Q4 2021 Feb 10, 2022	BUY	$0.89 - $1.66 $222,500 - $415,000	250,000 New	250,000 $240,000

929K

Ticker TLSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,273,000
Market Cap $98.2M
Description
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, m...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.